Menu

Risk-based Monitoring Considerations in Rare Disease Trials

In this white paper "Risk-based Monitoring Considerations in Rare Disease Trials," learn how PPD created an adaptive and intelligent monitoring strategy uniquely tailored to rare and uncommon diseases utilizing individual patient data points. PPD’s approach maintains a focus on quality and timely data using a detailed protocol risk assessment process and Preclarus®, a robust portfolio of technology solutions with real-time data.

To download the white paper, please complete the form below. Fields marked with * are required. Pharmaceutical Product Development, LLC and its affiliates (together “PPD”) will use the information you provide on this page for the purpose of sending you the requested white paper and possibly following up with you. Important information on how PPD handles personal data and what rights you may have under data privacy laws are included within PPD’s Global Privacy Policy.


Preclarus Risk-based Monitoring White Paper

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2018 Pharmaceutical Product Development, LLC. All rights reserved.